Karen Ferrante - Progenics Pharmaceuticals Director
Director
Dr. Karen Ferrante, M.D., is an Independent Director of Progenics Pharmaceuticals Inc. Dr. Ferrante was appointed head of RD and chief medical officer of Tokai Pharmaceuticals, Inc., a privatelyheld biopharmaceutical company developing treatments for prostate cancer and other hormonally driven diseases. From 2007 to 2013, Dr. Ferrante held senior positions at Millennium Pharmaceuticals and its parent company, Takeda Pharmaceuticals, most recently as Oncology Therapeutic Area and Cambridge USA Site Head. From 1999 to 2007, she held positions of increasing responsibility at Pfizer Global Research Development, culminating as Vice President, Oncology Department. She began her career in the pharmaceutical industry in 1995 as Associate Director of Clinical Oncology at BristolMyers Squibb Company. For more than a decade prior, she was at the New England Deaconess Hospital in Boston, where she completed her internship and residency in internal medicine followed by her fellowship in hematology and oncology. While at Beth Israel Deaconess, she served as Instructor, Clinical Instructor and Clinical Fellow in Medicine at the Harvard Medical School, and previously was a Bacteriologist for the City of Providence, Rhode Island Water Supply Board since 2014.
Age | 60 |
Tenure | 10 years |
Phone | 646 975-2500 |
Web | www.progenics.com |
Progenics Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.4869) % which means that it has lost $0.4869 on every $100 spent on assets. This is way below average. Progenics Pharmaceuticals' management efficiency ratios could be used to measure how well Progenics Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 54.63 M in liabilities with Debt to Equity (D/E) ratio of 1.17, which is about average as compared to similar companies. Progenics Pharmaceuticals has a current ratio of 2.83, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Progenics Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Progenics Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Progenics Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Progenics to invest in growth at high rates of return. When we think about Progenics Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Similar Executives
Showing other executives | DIRECTOR Age | ||
Leonard Becker | Universal Display | 91 | |
Elizabeth Gemmill | Universal Display | 72 | |
Michael Binney | Emerson Radio | 65 | |
Arturo Sarukhan | Playa Hotels Resorts | 52 | |
Debra SmithartOglesby | Cedar Fair LP | 65 | |
Kin Yuen | Emerson Radio | 64 | |
Richard Fried | Playa Hotels Resorts | 50 | |
David Berg | Planet Fitness | 57 | |
Stephen Haggerty | Playa Hotels Resorts | 49 | |
Michael Layman | Planet Fitness | 32 | |
Lauri Shanahan | Cedar Fair LP | 57 | |
Keith Hartley | Universal Display | 75 | |
Daniel Hirsch | Playa Hotels Resorts | 42 | |
Marc Grondahl | Planet Fitness | 48 | |
Mark Manski | Emerson Radio | 63 | |
Frances Rathke | Planet Fitness | 61 | |
Governor Benson | Planet Fitness | 68 | |
Kareem Sethi | Emerson Radio | 41 | |
Richard Elias | Universal Display | 64 | |
David Olivet | Cedar Fair LP | 57 | |
Thomas Klein | Playa Hotels Resorts | 55 |
Management Performance
Return On Equity | -1.0E-4 | |||
Return On Asset | -0.49 |
Progenics Pharmaceuticals Leadership Team
Elected by the shareholders, the Progenics Pharmaceuticals' board of directors comprises two types of representatives: Progenics Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Progenics. The board's role is to monitor Progenics Pharmaceuticals' management team and ensure that shareholders' interests are well served. Progenics Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Progenics Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
Jeffrey Summer, Senior Vice President - Strategy and Performance | ||
Patrick Fabbio, CFO and Sr. VP | ||
Nitya Ray, Sr. VP of Manufacturing | ||
David Scheinberg, Independent Director | ||
Ann Assumma, Vice President - Regulatory Affairs | ||
Peter Crowley, Independent Chairman of the Board | ||
Michael Kishbauch, Director | ||
Bradley Campbell, Independent Director | ||
Karen Ferrante, Director | ||
Huw Jones, Vice President - Commercial | ||
Vivien Wong, Vice President - Product Development | ||
Melissa Downs, IR Contact Officer | ||
Benedict Osorio, Senior Vice President - Quality | ||
Mark Baker, CEO, Director | ||
Nicole Williams, Independent Director | ||
Bryce Tenbarge, Vice President - Commercial |
Progenics Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Progenics Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -1.0E-4 | |||
Return On Asset | -0.49 | |||
Profit Margin | 12.67 % | |||
Operating Margin | (171.72) % | |||
Current Valuation | 370.66 M | |||
Shares Outstanding | 86.6 M | |||
Shares Owned By Insiders | 9.60 % | |||
Shares Owned By Institutions | 76.10 % | |||
Number Of Shares Shorted | 5.53 M | |||
Price To Earning | (103.33) X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Progenics Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Progenics Pharmaceuticals' short interest history, or implied volatility extrapolated from Progenics Pharmaceuticals options trading.
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Progenics Pharmaceuticals using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Other Consideration for investing in Progenics Stock
If you are still planning to invest in Progenics Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Progenics Pharmaceuticals' history and understand the potential risks before investing.
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes |